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Summary Human neuroblastoma cells grown as tumour spheroids were briefly incubated with a conjugate of
1311 and an anti-human neuroectodermal monoclonal antibody UJ 1 3A. Unbound 1311 was removed by
washing and the spheroids observed in culture conditions for up to 4 weeks. Spheroid response to irradiation
was evaluated as time to reach 10x treatment volume and proportion of spheroids sterilised. Spheroid
growth was found to be affected by both the activity of 131I-UJ13A and the duration of the incubation.
Na[131I], 1311-HSA, 1311 labelled non-specific antibody and unlabelled antibody were found to be relatively
ineffective compared to 1311-UJ 13A. The tumour spheroid model has applications in the evaluation of
antibodies or antibody fragments and different radionuclides which may be considered for radioimmunother-
apy of micrometastases.
The use of monoclonal antibodies conjugated to cytotoxic
agents as cancer therapy is most promising for the treatment
of small numbers of tumour cells, such as sub-clinical
metastases (Kemshead, 1985; Wheldon et al., 1988). Radio-
immunotherapy using 1311 conjugated to antibodies is under
clinical investigation in several centres (Carrasquillo et al.,
1984; Kemshead et al., 1984; Order et al., 1980). Most
experimental work is presently being performed using xeno-
grafts of human tumour in nude mice (Hagan et al., 1986;
Pimm & Baldwin, 1985).
Here we describe the use of an in vitro experimental model
which is suitable for laboratory assessment of antibody-
targeted radiotherapy of microscopic tumours.
Human tumour cell lines may often be grown in the form
of tumour spheroids which are cellular aggregates which
grow by division in the periphery (Sutherland et al., 1971;
Yuhas et al., 1977). Tumour spheroids in vitro resemble
micrometastases during the avascular phase of their develop-
ment (West et al., 1980). In these experiments we have
grown a human neuroblastoma cell line (NBl-G) in the
form of tumour spheroids. The cell line NBI-G is a recently
established derivative of a neuroblastoma tumour whose
origin, genetics, cytogenetics, antigenicity and radiobiology
have been characterised (Wheldon et al., 1985; Carachi et al.,
1987). We have used this spheroid line to evaluate the
effectiveness of antibody targeted irradiation of neuroblas-
toma spheroids with 131I conjugated to the mouse-anti-
human neuroectodermal monoclonal antibody UJ13A which
has been shown to bind to human neuroblastoma cells
(Allan et al., 1983).
Materials and methods
Monoclonal antibodies
UJ13A, a neuroectodermal specific monoclonal antibody
(Allan et al., 1983; Kemshead, 1985) was kindly provided by
Dr J.T. Kemshead (Imperial Cancer Research Fund). This
antibody has been shown to bind to NB1-G cells by indirect
immunofluorescence staining (Carachi et al., 1987). In most
experiments the control used was Na[13 3I]. In addition, some
experiments were carried out using human serum albumin
(HSA) and the monoclonal antibody T2.10 (also provided by
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Dr J.T. Kemshead, and shown not to bind to NBI-G cells)
as the controls.
lodination of both monoclonal antibodies and HSA was
carried out with Na[131I] carrier free (IBS30 Amersham)
using the lodogen method (Epenetos et al., 1982), 100 ug
antibody being incubated with 37MBq 1311. The iodination
was allowed to proceed until optimal incorporation of the
radiolabel had occurred. The efficiency of binding of 131I to
antibody was determined by thin layer chromatography and
binding efficiencies of 80-90% were routinely obtained.
NBI-G tumour spheroids
A human neuroblastoma cell line NB1-G was used for the
study (Wheldon et al., 1985; Carachi et al., 1987). Multicel-
lular tumour spheroids were initiated by detaching cells in
monolayer culture with trypsin, and placing 0.5 x 106 cells in
25cm2 flasks base coated with 1% 'Noble' agar containing
5 ml Eagles Minimum Essential medium (MEM) with 15%
foetal calf serum (FCS). Alternatively 1 x 106 cells were
placed in 50 ml medium in 100ml Techne (Cambridge)
spinner vessel, stirring at 40 rpm. Following 4-5 days incuba-
tion at 37°C in 5% C02, spheroids of around 200 jum in
diameter were obtained.
Incubation of spheroids with monoclonal antibody
Aliquots of around 40 spheroids were transferred into
universal containers and incubated in 5 ml MEM containing
15% FCS and 44mM Nal. To the spheroids was added
Na[131I] or 1311 labelled antibody at the activities shown in
Tables I and II. The spheroids were exposed to Na[13'I] or
1311-UJI3A for 2 h at 37°C. In a subsequent experiment, the
activity of 131I-UJ13A was approximately equal in three
aliquots of spheroids and the incubation time was varied
(Table IV). Some preliminary work with larger spheroids
was also undertaken.
Following the incubation period, the spheroids were
washed by allowing them to sediment and draining off the
incubation medium. This was replaced with 5ml of fresh
medium containing 44mM Nal. This procedure was repeated
6 times in total.
Spheroids were then transferred into individual agar
coated wells of a 24 well test plate (Linbro) with one plate of
cells being used for each universal container. The wells
contained 0.5 ml medium having 15% FCS but no Nal
added. Wells were replenished at weekly intervals with 0.5 ml
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fresh medium. The growth of spheroids was quantitated by
measuring spheroid volume three times weekly using an
image analysis system.
Experiments were continued until 50% or more of the
spheroids in each plate measured 1,000 im in diameter or for
up to 30 days (as the wells would not accommodate further
aliquots of fresh medium) whichever was the sooner. By 30
days there was a clear demarcation between regrowing and
non-regrowing spheroids.
Results
The effect of radiolabelled UJ13A on NB1-G spheroid
growth was determined by incubating spheroids with 2
activities of labelled monoclonal antibody and comparing
this with the effect of Na[1311]. The resulting growth curves
are shown in Figure 1. A lateral displacement of the growth
curves is observed at the higher activity of 13 I-UJ13A. The
indicated bars are -95% confidence limits on the median of
log volume measured in pm3 (Colquohoun, 1971).
Table I shows the results of3 experiments where spheroids
were exposed to a range of activities of 131I-UJ13A. Results
are expressed as the median time taken for spheroids to
reach 10 times the original volume, and the proportion of
spheroids sterilised (i.e. failed to regrow by 30 days).
Both the proportion sterilised and the time taken for the
spheroids to reach 10 times their original volume can be seen
to increase with increasing activity of 13 I-UJ13A. At the
highest activity of '3II-UJ13A used in experiments 1 and 2,
more than half the spheroids were sterilised and therefore
failed to reach x original volume so the median time to
reach this endpoint cannot be defined, consequently only the
proportion sterilised data are shown for this activity. These
results should be compared with the effect of Na[131] on
spheroid growth as summarized in Table II. This shows that
spheroid growth is not visibly affected by Na['3II] at activity
levels below 73 MBq. This is 10 times the activity necess-
ary to produce a comparable effect using 131I-UJ13A (see
Table I).
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Figure 1 NB1-G spheroid regrowth curves (median log volume
in m3m+95% confidence limits) as a function of time following
incubation with the following: (x) Control; (0) 6.48 MBq
Na['311]; (0) 5.48 MBq '1I-UJ13A; (I) 13.95 MBq
'311-UJ13A.
Table I Dose-response relationship of activity of 131I-UJ13A and effect on spheroid growth
Activity of Time to reach lOx
131jIUJJ3A treatment volume Proportion
added (MBq) (days) sterilised
Experiment I
0 7.2 (6.8-7.8) 0
5.48 9.6 (8.2-11.3) 0.05
13.95 15.1 (12.4->30) 0.33
27.82 - 0.77
Experiment 2
0 9.5 (7.7-10.5) 0
6.88 14 (12.0->30) 0.05
13.69 27 (15.8->30) 0.36
27.49 - 0.50
Experiment 3
0 7.0 (6.7-7.5) 0
6.14 9.7 (8.6-12.7) 0.10
16.10 8.1 (7.2-10.9) 0.10
27.45 25 (17.4->30) 0.48
1. Median values with 95% confidence limits
(Colquohoun, 1971). 2. An upper confidence limit
cannot be calculated where this exceeds the
duration of the experiment (30 days). 3. Medians
cannot be calculated when >50% of spheroids
were sterilised.
Table II Effect of Na[1311] on spheroid growth
Activity of Time to reach 10 x
Na['311] treatment volume
alded (.vf Bq) (days)
Experiment 1
0
6.36
13.28
28.56
Experiment 2
0
21.50
43.33
79.55
Experiment 3
0
40.7
73.3
181.7
7.2 (6.8-7.8)
6.6 (6.3-6.9)
7.1 (6.8-7.5)
7.4 (7.2-7.9)
6.9 (5.9-8.0)
5.3 (4.7-6.1)
5.5 (4.9-6.3)
6.5 (6.0-6.9)
8.0 (7.4-8.2)
7.4 (6.9-7.9)
9.6 (8.3-11.2)
16.4 (13.2-21.8)
Proportion
sterilised
0
0
0
0
0
0
0
0
0
0
0
0.14
1. Median values with 95% confidence limits.
Additional experiments have shown that UJ13A alone has
no effect on spheroid growth, and that 1311 labelled human
serum albumin, and 131I labelled monoclonal antibody
T2.10, which does not bind to NB1-G cells, have only the
same effect on spheroid growth as Na[131I].
In order to determine if the spheroids are receiving a
greater radiation dose from 1311-UJ13A during the 2h
incubation period or during the month-long growth phase
following the washing procedure, the activity of 1311-UJ13A
associated with the spheroids was quantified immediately
after the 6 washes in fresh medium and at time intervals
during the period of spheroid growth. Results are shown in
Table III. It can be seen that a much greater 1311 activity
remains associated with spheroids exposed to 131I-UJ13A
than with those exposed to Na[1311].
An experiment was also conducted where the activity of
131I-UJ13A added to 3 aliquots of spheroids was approxi-
mately equal, but the length of the incubation time was
varied. Table IV shows that the time for spheroids to reach
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Table III
Activity associated
per spheroid (Bq)
Source of Activity
irradiation added (MBq) 1 2 3 4
Na['311] 52.54 22 0 0 0 131I-UJI3A 38.11 520 66 53 75
Measurements were made: 1. Immediately following wash-
ing procedure; 2. After transfer to multiwell plates; 3. On
day 7; 4. On day 14.
Table IV Comparison of effect on spheroid growth of
altering exposure time to 13'I-UJ13A
Activity oJ lime to reach
131I-UJ13A Incubation IOx treatment Proportion
added (MBq) time (h) volume (days) sterilised
0 2 6.9 (5.9-7.9) 0
17.28 1 6.8 (6.2-7.7) 0
19.68 1.5 14.6 (10.4-18.2) 0.39
18.57 2 - 0.58
1. Median values with 95% confidence limits; 2. Median
cannot be calculated as >50% of spheroids sterilised.
10 times the treatment volume increases with increasing
length of incubation time. In the case of spheroids incubated
for 2 h with '3II-UJl3A, the proportion sterilised was too
great to allow evaluation of the spheroid growth endpoint.
The responses of two different sizes of spheroids, 200pm
and 450pm diameter, to incubation with varying levels of
131I-UJ13A are compared in Figure 2. It can be seen that
the effect of 13 I-UJl3A on the growth of both large and
small spheroids is similar. It would appear from this result
that both the large and the small spheroids are being
irradiated to the same extent.
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Figure 2 Time taken for median volume to reach 10 times
original value and estimated 95% confidence limits as a function
of activity of '1I-UJ13A. (0) Spheroids with initial diam.
200,um. (x) Spheroids with initial diam. 400,um. Note: Arrow
indicates that the upper confidence limits cannot be calculated as
this exceeds the duration of the experiment.
Discussion
The results demonstrate a dose-response relationship
between radiation damage, evaluated as a delay in spheroid
growth or proportion spheroids sterilised, and the activity of
13'I associated with UJ13A at incubation. Similar activities
of Na[1311], however, were not found to affect growth of the
spheroids, which would suggest that exposure to 13 1-UJI3A
resulted in binding of the agent to the spheroids. This was
supported also by the negative findings on incubation with
similar activities of 131I-HSA and I311-T210. Studies with
unlabelled UJ13A, which showed no effect on growth, would
suggest that the effect on spheroid growth of 1311-UJl3A is
radiation induced.
Significant effects were observed with Na[131I] only at
incubation activities of 180MBq where the estimated radia-
tion dose during 2h incubation (after allowing for rapid
settling of the spheroids on the base of the incubation vessel)
was in the region of 4Gy, one half of the dose to a
continuum of 131I at a concentration of 36MBqml-1.
Some attempts were made to quantify the extent to which
131I-UJ13A was bound to the spheroids. In one study where
spheroids were incubated with 38 M Bq for 2h, it was found
that at the end of the incubation period, and after repeated
washing, -520 Bq of 1311 were associated with each spher-
oid. Using theoretical estimates (Humm, 1986) of the
absorbed fraction of 131I #-particles for very small spheres
(-200pm in this case) it can be calculated that this activity
of 1311 would deliver -2Gyh-1 to each spheroid. If this
binding of 1311-UJ13A took place early during the incuba-
tion stage, then clearly radiation exposure over a long period
would be substantial. Subsequent measurements of spheroid
associated activity during the growth phase, showed that a
large proportion of the material left the spheroids rapidly.
Within 2h the estimated activity per spheroid was only 15%
of the initial value (66Bq/spheroid). A proportion of the
activity appeared, however, to be firmly bound with there
being - 10 Bq/spheroid at day 7 of the growth phase. Similar
studies with Na[13'I] revealed that only 22Bq were asso-
ciated with each spheroid at the end of the incubation and
repeated washing. This activity completely removed from the
spheroids during the first 2 h following the end of the
incubation period.
This result together with the observation that increasing
time of exposure to 131I-UJ13A increases the effect on
spheroid growth would suggest that the radiation dose is
delivered partly by migration towards and binding of the
radionuclide to the spheroids during the incubation period,
and partly by a small amount of firmly bound residual
activity being associated with each spheroid during the
growth period.
It has been shown (Wheldon et al., 1985) that spheroids
irradiated with 2.5Gy 4MeV X-rays as single acute expo-
sures take 14 days to grow to 10 x original volume. NBI-G
cells grown as spheroids have little capacity for repair of
sub-lethal damage (Wheldon et al., 1986) therefore, the effect
of protracted exposures should be similar to that of acute
exposures of the same total dose. From Figure 1 it can be
seen that 13.95 MBq 1311 given as 131I-UJ13A also results in
the spheroids requiring 14 days to grow to 10 x original
volume. In addition the measured activities of 1311 associated
with each spheroid would give a dose of the order of 2.5 Gy.
This allows some comparison of the effect of antibody-
targeted therapy and X-rays on spheroid growth in this
system.
The similarity in effect of 1311-UJ13A on spheroids of
200gm and 450gm diameter would suggest that the cells of
both large and small spheroids are being irradiated to the
same extent. This is the expected result when using 1311 as
the radionuclide as the ,B particle range is sufficient to
irradiate all the cells of a 450 jm spheroid even if only
bound to the outer layer. The distribution of antibody-
isotope conjugates within spheroids is likely to be of greater
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importance for radionuclides having shorter range emissions.
A possible application of the spheroid model may be in
evaluating antibody-targeted treatment using unfamiliar
radionuclides. Short range a and 3 emitters, which will
probably prove more useful than 1311 as therapeutic agents,
present difficult dosimetric problems which are compounded
by the increased importance of the distribution of the
radionuclide conjugate within a tumour. Micrometastases
though the most promising targets for antibody-guided ther-
apy given systematically present the most difficult dosimetric
problems (Humm, 1986). An in vitro model allowing opera-
tional evaluation of effective dose to micrometastases-like
tumour cell populations delivered by antibody-conjugated
radionuclides should be a useful experimental tool.
The NBl-G cell line has low capacity for repair of sub-
lethal damage and therefore would not be expected to be
significantly spared by low dose rate as activity falls. A
tumour line with greater capacity for repair might be spared
during the low dose rate phase of the growth period
following the incubation. It is suggested that the experimen-
tal system described here provides a model for the quantita-
tive evaluation of antibody-targeted therapy which could be
applied to a number of different tumour types. Further study
of the tumour spheroid model for radioimmuno-therapy of
micrometastases therefore seems warranted.
The work was supported by a grant from the Cancer Research
Campaign.
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